Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/1995
12/20/1995EP0687249A1 Balanoids
12/20/1995EP0687179A1 Use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders
12/20/1995EP0687178A1 Use of 2h-1,2,4-benzothiadiazine 3(4h)-one 1,1 dioxide derivatives as non-competitive nmda receptor antagonists
12/20/1995EP0687177A1 Use of lamotrigine for treating aids-related neural disorders
12/20/1995EP0687176A1 Use of riluzole for treating aids-related neural disorders
12/20/1995CN1113487A Method for preparing pharmaceutically active CNS compounds
12/20/1995CN1113437A A process for preparing a pharmaceutical composition containing benzothiazole compounds
12/19/1995US5476867 Pharmaceutical compositions
12/19/1995US5476857 Imidazopyridines
12/19/1995CA1337770C Hydrocarbon substituted pyrrolidinones
12/19/1995CA1337767C Indolocarbazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
12/14/1995WO1995033997A1 Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
12/14/1995WO1995033829A1 Pantropic neurotrophic factors
12/14/1995WO1995033752A1 Endothelin receptor antagonists
12/14/1995WO1995033750A1 Corticotropin releasing factor antagonists
12/14/1995WO1995033747A1 Novel 1,1-bis(heteroazolyl)alkane derivatives and their use as neuroprotective agents
12/14/1995WO1995033744A1 Tachykinin (nk1) receptor antagonists
12/14/1995WO1995033743A1 Piperazine derivatives as 5ht1a antagonists
12/14/1995WO1995033729A1 Serotonin 5-ht1a and dopamin d2 receptor ligands
12/14/1995WO1995033727A1 Substituted pyrazoles having corticotropin-releasing factor (crf) antagonist activity
12/14/1995WO1995033723A1 Phenoxyalkyl substituted piperidines, pyrrolidines, morpholines and thiomorpholines as calcium channel antagonists
12/14/1995WO1995033722A1 Phenoxyalkyl substituted piperidines, pyrrolidines, morpholines and tiomorpholines as calcium channel antagonists
12/14/1995WO1995033721A1 4-aryl-1-(indanmethyl, dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl)piperidines, tetrahydropyridines or piperazines
12/14/1995WO1995033486A1 Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof
12/14/1995WO1995033480A1 Pigment epithelium-derived factor: characterization, genomic organization and sequence of the pedf gene
12/14/1995WO1995033475A1 Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
12/14/1995WO1995033455A1 Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
12/14/1995CA2704083A1 Pigment epithelium-derived factor: characterization, genomic organization and sequence of the pedf gene
12/14/1995CA2192468A1 Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
12/14/1995CA2192218A1 Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
12/14/1995CA2192113A1 Serotonin 5-ht 1a and dopamin d2 receptor ligands
12/14/1995CA2192112A1 4-aryl-1-(indanmethyl, dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl)piperidines, tetrahydropyridines or piperazines
12/14/1995CA2191996A1 Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
12/14/1995CA2190128A1 Novel 1,1-bis(heteroazolyl)alkane derivatives and their use as neuroprotective agents
12/14/1995CA2187531A1 Tachykinin (nk1) receptor antagonists
12/13/1995EP0686637A1 Tetracyclic 1,4-oxazine derivatives, process for their preparation and pharmaceutical compositions containing them
12/13/1995EP0686629A2 Cyclohexyl tachykinine receptor antagonists
12/13/1995EP0686397A2 Use of chondroitin sulphate proteoglycans for protection of neurons
12/13/1995EP0686394A1 Use of N-[[5-(naphthales-1-yl)-1,3-dioxan-2-yl]alkyl]acetamide derivatives for the preparation of medicaments for use in the treatment of neurodegenerative disorders
12/13/1995EP0686203A1 Compounds and methods for the diagnosis, treatment and prevention of diseases of cell death
12/13/1995EP0686155A1 Xanthine derivatives as adenosine a1 receptor antagonists
12/13/1995EP0686145A1 New compounds
12/13/1995EP0686144A1 New compounds
12/13/1995EP0573473B1 4-[(2-benzothiazolyl)methylamino]-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol
12/13/1995CN1113240A Oxazolidone derivative
12/13/1995CN1113236A Non-peptidyl tachykinin receptor antagonists
12/12/1995US5475106 Agonist for cholecystokinin and gastrin receptors; nervous system, gastrointestinal disorders
12/12/1995US5475105 N-substituted azabicycloheptane derivatives
12/12/1995US5475032 Treating strokes
12/12/1995US5475020 Selective vasoconstrictors
12/12/1995US5475018 Antiinflammatory agent, antiarthritic agent; analgesics and antipyretics
12/12/1995US5475015 Benzimidazole derivatives, their preparation and pharmaceutical use
12/12/1995US5475014 Monoamine oxidase inhibor; antidepressant
12/12/1995US5475008 Quinolone derivatives
12/12/1995US5475007 Preventing convulsions
12/12/1995US5475004 Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease
12/12/1995US5475002 Use of 1-(5-oxohexyl)-3-methyl-7-n-propylxanthine in vascular surgery
12/12/1995US5474995 Phenyl heterocycles as cox-2 inhibitors
12/12/1995US5474978 Insulin analog formulations
12/11/1995CA2151113A1 Imidazolinyl tachykinin receptor antagonists
12/11/1995CA2150992A1 Cyclohexyl tachykinin receptor antagonists
12/09/1995CA2150960A1 Use of n-[[5-(naphthalen-1-yl)-1,3-dioxan-2-yl]alkyl] -acetamide derivatives for the preparation of medicinal products which are useful in the treatment of neurodegenerative disorders
12/07/1995WO1995032973A1 The preparation of nalbuphine having low levels of beta-epimer
12/07/1995WO1995032972A1 [a]-ANNELATED PYRROLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF
12/07/1995WO1995032971A1 [a]-ANNELATED PYRROLE DERIVATIVES AND PHARMACEUTICAL USES THEREOF
12/07/1995WO1995032970A1 (a)-ANNELATED PYRROLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF
12/07/1995WO1995032967A1 Amide derivatives having 5ht1d-antagonist activity
12/07/1995WO1995032966A1 Indole derivatives as prodrugs of 5-ht1-like receptor agonists
12/07/1995WO1995032949A1 Gastrin and cck antagonists
12/07/1995WO1995032948A1 Quinoline derivatives as tachykinin nk3 receptor antagonists
12/07/1995WO1995032724A1 Glial mitogenic factors, their preparation and use
12/07/1995WO1995032715A1 Nitric oxide donor composition and method for treatment of anal disorders
12/07/1995WO1995030435A3 Compositions and treatment for multiple sclerosis
12/07/1995WO1995029165A3 Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors
12/07/1995DE4419315A1 New hetero- and oxo-pyrrolizine derivs.
12/07/1995DE4419247A1 New pyrrolizine keto-acid, keto-ester and carboxamide derivs.
12/07/1995DE4419246A1 New hetero-aryl substd. pyrrolizine derivs.
12/07/1995CA2191745A1 [a]-annelated pyrrole derivatives and pharmaceutical uses thereof
12/07/1995CA2191085A1 Glial mitogenic factors, their preparation and use
12/06/1995EP0685466A1 3-Heteroaliphatyle-and 3-hetero-(aryle)-aliphatyle-2(1H)-quinolone derivatives
12/06/1995EP0684953A1 Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
12/06/1995EP0684949A1 Chemical compounds
12/06/1995EP0684944A1 Coupling product obtained from hystamine and an amino acid
12/06/1995EP0673259A4 A method for transplanting cells into the brain and therapeutic uses therefor.
12/06/1995EP0575429B1 Treatment of cognitive disorders
12/06/1995EP0500847B1 Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
12/06/1995EP0491814B1 Tetracyclic imidazoquinazoline derivatives, preparation and pharmaceutical compositions
12/06/1995CN1112836A Meicinal prepn. "Kexianling" for curing epilepsy
12/05/1995US5473077 4-aminopyrrolidine-2,4-substitude independently with carboxylic acid or 5-tetrazolyl for treating nervous system disorders and psychological disorders
12/05/1995US5473072 Process for the preparation of high purity buspiron and the hydrochloride thereof
12/05/1995US5472968 Spiro[cycloalkylbenzene-1,1'-(1',2',3',4'-tetrahydro-isoquinolines)] having neuroprotective properties
12/05/1995US5472966 Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
12/05/1995US5472961 Acetamides
12/05/1995US5472959 Hypotensive agents, congestive heart failure
12/05/1995US5472947 Application of 4-carbamoyl-1-β-D-ribofuranosyl imidazolium-5-olate to the treatment of multiple sclerosis
12/05/1995US5472943 Co-administering agonist and antagonist
12/05/1995US5472714 Double-layered oxcarbazepine tablets
12/05/1995US5472712 A drug substrate containing an active agent coated with ethyl cellulose being cured at a temperature greater than the glass transition temperature; storage stability, sustained release
12/05/1995CA2001194C Use of resiniferatoxin and analogues thereof to cause sensory afferent c-fiber and thermoregulatory desensitization
12/03/1995CA2150645A1 3-heteroaliphatyl- and 3-hetero(aryl)aliphatyl-2(1h) -quinolone derivatives
1 ... 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 ... 1833